TENORETIC 50 Drug Patent Profile
✉ Email this page to a colleague
When do Tenoretic 50 patents expire, and when can generic versions of Tenoretic 50 launch?
Tenoretic 50 is a drug marketed by Twi Pharms and is included in one NDA.
The generic ingredient in TENORETIC 50 is atenolol; chlorthalidone. There are thirty-four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the atenolol; chlorthalidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tenoretic 50
A generic version of TENORETIC 50 was approved as atenolol; chlorthalidone by TWI PHARMS on May 31st, 1990.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TENORETIC 50?
- What are the global sales for TENORETIC 50?
- What is Average Wholesale Price for TENORETIC 50?
Summary for TENORETIC 50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| DailyMed Link: | TENORETIC 50 at DailyMed |
Pharmacology for TENORETIC 50
| Drug Class | Thiazide-like Diuretic beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for TENORETIC 50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TENORETIC 50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TENORETIC 50
See the table below for patents covering TENORETIC 50 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Yugoslavia | 193475 | ⤷ Sign Up | |
| Norway | 128653 | ⤷ Sign Up | |
| South Africa | 7207789 | ⤷ Sign Up | |
| Israel | 33931 | 3-ALKYLAMINO-1-PHENOXY-2-PROPANOL DERIVATIVES | ⤷ Sign Up |
| Czechoslovakia | 153066 | ZPUSOB VYROBY FENOXYPROBANOLAMINUZ | ⤷ Sign Up |
| U.S.S.R. | 403162 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
